Press Releases
-
May 11, 2020
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of senior...
-
May 6, 2020- Bank of America Global Research Health Care Conference on May 14
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in the Bank of America Global Research Health Care Conference on May 14, 2020 at 2:20pm ET and the RBC...
-
May 3, 2020
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR AG (DiNAQOR), a gene therapy platform...
-
Apr 29, 2020- U.S. Marketing Application for Valoctocogene Roxaparvovec for Severe Hemophilia A Accepted by FDA under Priority Review with Prescription Drug User Fee Act (PDUFA) action date of August 21, 2020
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2020 2019 % Change Total Revenues $ 502.1 $ 400.7 25 % Net Product Revenues...
-
Apr 22, 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...